Temporary organ displacement coupled with image-guided, intensity-modulated radiotherapy for paraspinal tumors by Evangelia Katsoulakis et al.
Katsoulakis et al. Radiation Oncology 2013, 8:150
http://www.ro-journal.com/content/8/1/150METHODOLOGY Open AccessTemporary organ displacement coupled with
image-guided, intensity-modulated radiotherapy
for paraspinal tumors
Evangelia Katsoulakis1, Stephen B Solomon2, Majid Maybody2, Douglas Housman4, Greg Niyazov3, Nadeem Riaz1,
Michael Lovelock3, Daniel E Spratt1, Joseph P Erinjeri2, Raymond H Thornton2 and Yoshiya Yamada1*Abstract
Background: To investigate the feasibility and dosimetric improvements of a novel technique to temporarily
displace critical structures in the pelvis and abdomen from tumor during high-dose radiotherapy.
Methods: Between 2010 and 2012, 11 patients received high-dose image-guided intensity-modulated radiotherapy
with temporary organ displacement (TOD) at our institution. In all cases, imaging revealed tumor abutting critical
structures. An all-purpose drainage catheter was introduced between the gross tumor volume (GTV) and critical
organs at risk (OAR) and infused with normal saline (NS) containing 5-10% iohexol. Radiation planning was
performed with the displaced OARs and positional reproducibility was confirmed with cone-beam CT (CBCT).
Patients were treated within 36 hours of catheter placement. Radiation plans were re-optimized using pre-TOD
OARs to the same prescription and dosimetrically compared with post-TOD plans. A two-tailed permutation test
was performed on each dosimetric measure.
Results: The bowel/rectum was displaced in six patients and kidney in four patients. One patient was excluded due
to poor visualization of the OAR; thus 10 patients were analyzed. A mean of 229 ml (range, 80–1000) of NS 5-10%
iohexol infusion resulted in OAR mean displacement of 17.5 mm (range, 7–32). The median dose prescribed was
2400 cGy in one fraction (range, 2100–3000 in 3 fractions). The mean GTV Dmin and PTV Dmin pre- and post-bowel
TOD IG-IMRT dosimetry significantly increased from 1473 cGy to 2086 cGy (p=0.015) and 714 cGy to 1214 cGy
(p=0.021), respectively. TOD increased mean PTV D95 by 27.14% of prescription (p=0.014) while the PTV D05
decreased by 9.2% (p=0.011). TOD of the bowel resulted in a 39% decrease in mean bowel Dmax (p=0.008)
confirmed by CBCT. TOD of the kidney significantly decreased mean kidney dose and Dmax by 25% (0.022).
Conclusions: TOD was well tolerated, reproducible, and facilitated dose escalation to previously radioresistant
tumors abutting critical structures while minimizing dose to OARs.
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Radiation treatment planning and delivery methods have
become increasingly conformal over the past 50 years.
The evolution from classical two-dimensional (2D) ap-
proaches into customized 3D techniques has been
sustained by the principle that better targeting enables ac-
curate dose delivery to tumor with concomitant dose* Correspondence: yamadaj@mskcc.org
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distribution, and reproduction in any mediumreduction to normal tissues. Conformal radiation was fur-
ther refined with the development of dose-sculpting tech-
niques, namely IMRT. These techniques have facilitated
tumor dose escalation while simultaneously decreasing
toxicity, resulting in improved outcomes. Dose intensifica-
tion is especially critical for the ablation of unfavorable
tumor histologies such as sarcoma, renal cell carcinoma,
chordoma, and non-seminomatous germ cell carcinoma
[1,2]. More recently, image-guided IMRT (IG-IMRT), with
3D imaging to verify position, has allowed delivery of
greater doses per fraction with marked accuracy. Theretral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cent to a critical structure. Temporary displacement of
critical organs at risk (OAR) away from the tumor during
treatment allows delivery of high-dose radiation while
minimizing dose to the adjacent OAR.
Multiple techniques aimed at shifting critical struc-
tures apart from the PTV have been employed in con-
ventionally fractionated conformal radiation. Simple
maneuvers such as moderate-deep inspiration breath
hold during radiation have achieved substantial internal
organ displacement in the treatment of left-sided breast
cancer, resulting in decreased cardiac dose [3]. Slightly
more invasive techniques have been examined in at-
tempts to physically separate the rectum from the pros-
tate in dose-escalation strategies for prostate cancer
treatment. Approaches have included collagen and hya-
luronic acid injections, as well as biodegradable balloon
implantation between the rectum and prostate [4,5]. A
prostate rectum separation of 10 mm significantly re-
duced mean V70 to the rectum by 83% (p<0.05), which
should reduce chronic rectal toxicity [6]. Due to lengthy
treatment times of conventional fractionation of up to 9
weeks, optimal spacers have yet to be routinely incorpo-
rated into clinical practice. Another technique to de-
crease dose to normal tissues through tighter margins
via target immobilization was the endorectal balloon
(ERB) which reduced maximal tumor displacement from
4 mm to ≤ 1 mm [7]. The use of ERB has been routine
in clinical practice in order to immobilize target, limit
intra and inter-fractional motion, and decrease normal
tissue toxicity through tighter margins.
Unlike tumors in the lung or prostate, paraspinal and
sacral/pelvic tumors bear a fixed topographical relation-
ship to the spine and pelvis. Treatment can sometimes
be limited by the proximity of the bowel or kidney. Vari-
ous organ displacement methods have been performed
to protect critical organs from thermal injury during
percutaneous image-guided radiofrequency tumor abla-
tion including gas, fluid, or balloons [8-11]. We thus
focused our efforts on manipulating the motion of crit-
ical structures at risk through temporary displacement.
Radiosurgery is an ideal platform for organ displace-
ment due to steep dose gradients and short fractionation
schemes. Seemingly small shifts in critical OARs can
translate into large improvements in tumor-ablative dose
delivery. In this paper, we present a cohort of patients
treated with tumor-ablative radiosurgery and temporary
organ displacement (TOD) for radioresistant tumors
that abutted critical normal tissues.
Materials and methods
Records of 11 consecutive patients with unfavorable
tumor histologies treated with TOD and IG-IMRT be-
tween 2/10 and 6/12 were retrospectively reviewed. Allpatients had at least one pretreatment scan [magnetic res-
onance imaging (MRI) or computed tomography (CT)]
that revealed close proximity of tumor and normal critical
structures. All patients were evaluated for TOD by a
multidisciplinary team including radiation oncologists,
neurosurgeons, and interventional radiologists.
TOD technique
In all cases, intravenous procedural conscious sedation
with midazolam and fentanyl is used. Under CT guid-
ance, a 21 G needle is used to access the potential space
between the OAR and the PTV. Using the Seldinger
technique, the needle is exchanged for an all-purpose
drain (6–10 Fr). Catheter placement and position verifi-
cation are performed under image guidance by fluoros-
copy and CT. Normal saline with 5-10% iohexol is
infused through the catheter in a stepwise manner of
20–50 cm3 boluses until an adequate displacement oc-
curs and is confirmed radiographically. Infused fluid dis-
places the OAR from the PTV. The infused volume is
absorbed by the body over time. After recovery in the
postanesthesia care unit, the patient is transported to
CT simulation.
Radiation technique
The immobilization technique at Memorial Sloan-
Kettering Cancer Center has been previously described
[12]. Briefly, the Memorial Sloan-Kettering Cancer Cen-
ter Body Cradle immobilization device uses pressure
plates applied laterally to the pelvic bones and ribs under
the arms with adjustable hand grips.
An all-purpose drain (APD) is used for TOD and is
placed approximately 4 hours prior to simulation. CT scan
is performed prior to CT simulation and TOD positioning
is re-assessed. Additional contrast material during simula-
tion is introduced through the APD on a case-by-case basis.
Typically, a 20–50 cm3 bolus of NS iohexol solution is in-
crementally introduced and satisfactory TOD is confirmed
by CT. After CT simulation, the patient is discharged upon
receiving catheter care education and is instructed to
administer 10 cm3 saline flushes every 24 h. Gross tumor
volume (GTV) is contoured using all available imaging
information from MRI and CT. Planning target volume
(PTV) consisted of clinical target volume plus a 3D margin
of 3 mm. The contrast-infused TOD space enables
visualization of OARs that are contoured separately.
A single fraction of 2400 cGy is prescribed for each le-
sion. An IG-IMRT plan is then designed to treat the PTV
to the prescription dose. Our institutional dose constraints
were used with maximal IG-IMRT point dose to the bowel
and rectum limited to 16 Gy in one fraction. The kidney
constraint was V10 Gy limited to 35% of total kidney vol-
ume in one fraction or V15 Gy limited to 35% in 3 frac-
tions. Patients were treated within 36 h of CT simulation.
Table 1 Patient characteristics, temporary organ
displacement of the bowel





1 Chordoma 80 M S3-4 10 2100
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consistency of TOD, we were able to estimate the degree
of critical organ shifts that a TOD would permit on the
planning CT simulation and subsequently confirm these
shifts with actual TOD prior to treatment delivery on the
same day.cGy/1
2 Chordoma 57 M S3-5 31 2400
cGy/1
3 Chordoma 76 F S3 21 2400
cGy/1
4 Sarcoma 76 F S3 22 2400
cGy/1
5 Chordoma 48 M S2-4 32 2400
cGy/1





Patients were treated within 36 h of catheter placement to
maintain flowing drainage and decrease the risk of catheter
blockage. For treatment delivery, good catheter flow is con-
firmed and the patient is positioned in the cradle on the
treatment couch, and cone-beam CT is obtained. The same
amount of contrast material used during initial catheter
placement is again introduced through the APD until satis-
factory TOD is achieved. After treatment is completed, the
catheter is removed by interventional radiology.Table 2 Patient characteristics, temporary organ
displacement of the kidneyDosimetric comparison: radiation planning without TOD
In patients who underwent CT simulation with TOD, diag-
nostic CT scans prior to TOD placement were fused with
CT simulation scans. OARs without displacement were
contoured for all patients on the fused planning scans. A
total of 10 IG-IMRT plans were generated for all patients
using the modified OAR with identical prescriptions and
normal tissue constraints as the TOD treatment plans. Dif-
ferences in dosimetry were quantified. Dose-insufficiency
measures were compared by examining GTV Dmin, PTV
Dmin, and D95. Dose homogeneity was evaluated by exam-
ining D05. Dose to critical structures was examined.
To determine the statistical significance of any differ-
ences between the two groups, the outcome of the study
was simulated numerically using a permutation test on
each of the dosimetric measures. For each patient, the
value of the measure was selected randomly for the TOD
and no-TOD values observed. The process is repeated for
each patient, and a sum statistic is created from the sum
of the randomly selected measures. A distribution of sum
statistics was generated by repeating the procedure 106
times. The p value was calculated from the proportion of
the distribution less than or equal to the sum statistic seen
in the data. Because the test being used is two-tailed, this





20 M L3 7 2400cGy/1
2 NSGCT 39 M L1 17 2850cGy/3
3* Sarcoma 52 M L2 7 3000cGy/3
4 NSGCT 61 M L2-3 13 2400cGy/1
Mean 11
§ Patient 1 had a solitary kidney.
* Patient 3 had a horseshoe kidney.Results
Between 2010 and 2012, 11 consecutive patients under-
went IG-IMRT with TOD. The first patient was ex-
cluded from this analysis secondary to lack of contrast
in injected saline during CT simulation, resulting in
poor visualization of the OAR, leaving 10 patients. All
patients had histologies traditionally thought to be
radioresistant (Tables 1 and 2). The median age was 56years (range, 20–80) with 3 women and 7 men. OARs
included bowel/rectum (n=6) and kidney (n=4).
TOD was achieved with a single APD (mean 8.5 F;
range, 6–10 F) in 9 patients. One patient had an occluded
catheter on treatment day, exchanged for a 12 × 40 mm
balloon catheter used for displacement. The mean volume
of NS solution with 5-10% iohexol used for organ dis-
placement was 229 mL (range, 80–1000 mL). One patient
had particularly difficult anatomy for which TOD catheter
placement by interventional radiology was not possible.
The technical success of TOD placement was thus 92%
(11/12). All eleven patients who had successful TOD place-
ment went on to receive radiation treatment. The mean
total procedural time for TOD placement including verifi-
cation was 87.5 minutes (range, 60–150). There were no
complications.
On axial CT, the TOD was well visualized as a
hyperdense region between the PTV and the bowel
(Figure 1b) or kidney (Figure 2b). Mean organ displacement
measured at the region of the smallest separation between
PTV and OAR prior to TOD was 17.5 mm. The
Figure 1 Axial imaging of a sacral chordoma treated to 2400c Gy. (a) Baseline computed tomography (CT) scan revealing pelvic sacral
tumor target adjacent to bowel at S2-4. (b) Cone-beam CT confirming temporary organ displacement (TOD) bowel. TOD is well visualized as a
hyperdense region (dark blue) between the planning target volume (pink) and bowel (orange). CBCT enables calculation of dose delivered to the
critical structures.
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equal to the measured displacement throughout the length
of the PTV.TOD of the bowel resulted in improved PTV coverage
Both GTV Dmin and PTV Dmin were compared pre- and
post- bowel TOD as shown in Figure 3a-b. The mean
GTV Dmin and PTV Dmin pre- and post-TOD signifi-
cantly increased from 1473 cGy to 2086 cGy (p = 0.015)
and 714 cGy to 1214 cGy (p = 0.021), respectively. The
mean PTV D95 prior to TOD also improved from 1737
cGy to 2359 cGy, or an increase of 27.14% of prescrip-
tion (p = 0.014) (Figure 3c). A sample DVH revealing
the dosimetric advantages of bowel TOD is shown in
Figure 4. In addition to providing improved PTV cover-
age, TOD improved dose homogeneity. The mean PTV
D05 significantly decreased from 2672 cGy to 2456 cGy,
or 9.2% of prescription (p = 0.011). TOD of the kidney
did not result in significant changes to PTV coverage or
dose homogeneity.Figure 2 Axial imaging of paraspinal non-seminomatous germ cell tu
scan revealing paraspinal target lesion adjacent to the kidney at L1. (b) ConTOD resulted in reduced dose to OAR confirmed by
cone-beam CT
The bowel Dmax was compared pre-TOD with actual
dose delivered by cone-beam CT as shown in Figure 3d.
Prior to TOD of the bowel, the IG-IMRT plans resulted
in a mean bowel Dmax of 1596 cGy. The actual mean
Dmax calculated from cone-beam CT with TOD was 974
cGy. The 39% decrease in mean bowel Dmax with TOD
was significant (p = 0.008).
The adjacent mean kidney dose, Dmax
, and V10 were also
compared pre-TOD with cone-beam CT (Figure 5a-c).
Mean kidney dose and Dmax significantly decreased with
TOD from 898 cGy to 676 cGy (p = 0.022) and 2942 cGy
to 2235 cGy (p = 0.023), respectively. Mean kidney V10
decreased from 31% to 11% (p =0.25).Discussion
Unfavorable tumor histologies require tumor ablative
doses to maximize local control. Image-guided techniques
have enabled conformal high-dose radiation in multiplemor treated to 2850 cGy. (a) Baseline computed tomography (CT)
e-beam CT confirming TOD kidney.
Figure 3 Dosimetric outcomes with temporary organ displacement (TOD), bowel. The bar graphs reflect pre-TOD dosimetry (blue), post-
TOD dosimetry (red), and dose delivered by cone beam computed tomography (green). (a) Planning target volume (PTV) Dmin, (b) gross tumor
volume (GTV) Dmin, (c) PTV D95, (d) bowel Dmax.
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few years, we have encountered patients with unique anat-
omy not amenable to radiosurgery. Specifically, the critical
OARs are alongside the tumor target and hinder safe de-
livery of radiation. To our knowledge, this is the first and
only series in the radiosurgery literature that introduces a
novel TOD technique into treatment planning and high-
dose radiation delivery.Figure 4 Dose volume histogram (DVH) reflecting dosimetric advanta
The planning target volume (PTV) D95 increased from 1351 cGy to 2372 cG
increased from 1025 cGy to 2262 cGy. The pre-TOD and post-TOD bowel D
by cone-beam computed tomography was 794 cGy. *DVH corresponds toIn this series, the mean displacement with the TOD was
greater in the bowel (21.8 mm) than the kidney (11 mm).
These are substantial shifts considering that the maximum
dose gradient with IMRT is 10% per millimeter, thereby
enabling high-dose therapy and maximizing local control.
It is well established that the excellent local control rates
observed for spinal metastases are dose dependent and
histology independent with high-dose single fractionges with temporary organ displacement (TOD), bowel.
y while the D05 decreased from 2711 cGy to 2516 cGy. The GTV Dmin
max were 1600 cGy and 743 cGy, respectively. Dose delivered to bowel
patient 3 in Table 1.
Figure 5 Dosimetric outcomes with temporary organ
displacement (TOD), kidney. (a) Adjacent kidney mean dose.
(b) Adjacent kidney Dmax. (c) Adjacent kidney V10.
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Dmin, PTV Dmin, and D95 are useful measures of dose in-
sufficiency and ultimately local failure. In a study examin-
ing local failures after high-dose single-fraction IGRT for
spinal metastases by Lovelock et al., GTV Dmin<15 Gypredicted for a 16% local failure rate compared with no
failures with GTV Dmin ≥15 Gy [14]. In this series, TOD
of the bowel significantly increased both the mean GTV
Dmin and PTV Dmin from 1473 cGy to 2086 cGy (p =
0.015) and 714 cGy to 1214 cGy (p = 0.021), respectively.
In addition to significantly improving PTV coverage,
TOD of the bowel significantly reduced mean rectal and
bowel Dmax by 39% to 974 cGy (p = 0.008). Every organ
maintains an individual dose-volume response pattern
largely influenced by organ architecture. The bowel com-
prises a chain of functional units, with serial-like organ be-
havior. Late bowel injury may manifest as obstruction,
bleeding, ulceration, fistula, persistent diarrhea, and perfor-
ation generally occurring weeks to months post-radiation
[15]. While dose-volume parameters have been extensively
reported and validated in both the bowel and rectum in
the setting of conventional radiation, consensus guidelines
are in development for high-dose IGRT. In the single-
fraction stereotactic body radiotherapy (SBRT) study for
pancreatic cancer to 25 Gy by Chang et al., <50% of the
duodenum received >12.5 Gy and the 50% isodose line was
not permitted to encompass the entire luminal wall. The
crude rate of grade ≥3 gastrointestinal toxicity was 9% [16].
In an analysis of patients with grade 2–4 gastrointestinal
toxicity following single-fraction SBRT, Murphy et al. dem-
onstrated a dose-dependent duodenal toxicity on 16% of
the treated cohort, which significantly correlated with V20
and Dmax. A Dmax of <23 Gy versus ≥23 Gy resulted in
12% versus 49% toxicity (p = 0.004) [17]. The median time
to toxicity was 6.3 months with a 1-year actuarial rate of
grade 2–4 toxicity of 29%. Ultimately, the goals of therapy
are to both maximize local control and limit toxicity. It is
essential that we maintain acceptable levels of toxicity for
these patients, on the order of <5%-10%. Our institutional
bowel and rectal constraints are conservative, with a bowel
and rectal Dmax of 16 Gy. TOD of the bowel/rectum was
effective and ensured limited dose to the bowel and rec-
tum. None of the patients in our series developed gastro-
intestinal toxicity.
Not surprisingly, TOD significantly decreased dose to
adjacent kidney. One patient had a single kidney while
another had a horseshoe kidney. The mean kidney dose
and Dmax decreased with TOD from 898 cGy to 676 cGy
(p = 0.022) and 2942 cGy to 2235 cGy (p = 0.023), re-
spectively. The kidney has a complex organization, with
cortex exhibiting parallel-organ structure while the
hilum and vascular trunk maintain a serial-organ struc-
ture. Dose constraints using SBRT are lacking and not
validated. In the current single-fraction spine SBRT trial
(RTOG 0631), a V8.4 Gy should be <200 cm3 total renal
cortex with grade 3 renal dysfunction as an endpoint
[18]. Our institutional constraints are largely extrapo-
lated from the liver SBRT literature with V10 Gy limited
to 35% of total kidney volume in one fraction or V15 Gy
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The subject of normal tissue constraints is compounded
for patients with one kidney [19]. Any substantial de-
crease in dose to the kidney is meaningful.
Unlike with bowel, TOD of the kidney did not signifi-
cantly improve target coverage. Possible reasons for this
include less organ displacement, smaller patient num-
bers, and an increased amount of OARs adjacent to tar-
get. Paraspinal tumors require target dose delivery while
ensuring that both the kidney and cord dose are kept
below tolerance. In contrast, for tumors confined to the
pelvis, bowel is often the only OAR. In the rare circum-
stance that a small portion of cauda is adjacent to the
pelvic target, dose constraints are less conservative than
cord constraints, Dmax 18 Gy versus 14 Gy. The safe de-
livery of radiation is foremost in our practice and, al-
though PTV coverage was not improved, TOD of the
kidney was essential in dose reduction to critical struc-
tures. As the technique is refined, it is likely that greater
displacement distance for kidney will be achieved.
The technique involves indwelling drainage catheters,
similar to percutaneous endoscopic gastrostomy tubes
and tenckoff catheters which are used in a various clin-
ical applications. Indwelling catheters carry a small risk
of infection with appropriate antiobiotic use, on the
order of 1% to less than 3% at 2 weeks [20,21]. More-
over, infection risk is strongly correlated to the duration
of catheter stay and frequent catheter hub access. The
risk of infection with this technique is low since indwell-
ing catheters were inserted for less than 36 h and infre-
quently accessed. In addition, NS 5-10% iohexol infusion
was selected as it is generally well tolerated in the peri-
toneal cavity and readily absorbed. Iohexal is often used
even in the presence of bowel perforation or bowel
obstruction for both diagnostic and interventional
radiology. Moreover, dose differences with contrast are
less than 0.1% with multiple beam IMRT and clinically
negligible [22].
The current study presents the feasibility and dosimetric
advantages of a compelling novel technique that tempor-
arily displaces critical structures in the pelvis and abdo-
men, enabling the safe delivery of tumor ablative doses.
Conclusions
By displacing critical OAR away from the tumor, bowel
and kidney doses were reduced by 25-39% and tumor
dose improved by 27% with bowel TOD. TOD was well
tolerated and reproducible, and facilitated dose escal-
ation while minimizing dose to OARs. TOD is a compel-
ling novel technique facilitating dose escalation to radio
resistant tumors abutting critical structures.
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